Cyclophosphamide

In this current research work the nanoparticles containing Cyclophosphamide using natural Gumghatti as a polymer has been formulated for the enhanced anticancer activity. The nanoprecipitation method has been utilized for the preparation of Cyclophosphamide comprising natural Gumghatti as polymer. The prepared nanoparticles have shown the average particle size, polydispersity index and zeta potential of 143.4 nm, 0.16 and 28.5 mV respectively. Further the encapsulation efficiency, percentage drug loading and percentage yield for all the formulations were substantial, especially for the trial 6 the values observed were 93.56, 83.55 and 76.54 respectively. The invitro release of Cyclophosphamide Gumghatti nanoformulations and were determined by dissolution tester by USP apparatus II in 900ml phosphate buffer pH 6.8. The dissolution media were maintained at 37±0.5°C with a paddle rotation speed at 50 rpm. The amount of drug used was equivalent to 15 mg at specified time intervals (5, 10 15, 20, 25 30 60, 90 and 120 minutes.) The results shows that prepared nanoparticles having 98.53 % of drug release in 120 minutes, further it indicates more than 95 % of drug release in 2 hours. Invivo anticancer activity has been performed using Swiss albino mice, the results indicated that the enhanced anticancer activity of the prepared nanoformulations.

Cyclophosphamide is well known anticancer drug used for the treatment of several types of cancers. In combination with other drugs cyclophosphamide is prescribed to treat breast cancer, leukemia and ovarian cancer. But cyclophosphamide reduces the production of blood cells from the bone marrow. In the present investigation to combat the toxicity of cyclophosphamide, aqueous extract of immunomodulator plant like Ashwagandha was studied against toxicity of cyclophosphamide. After administration of cyclophosphamide @ 250 mg/kg b.w. (tablet) orally by gastric intubation method to rats, marked reduction in total count of WBC, ALC and Platelets were observed and slightly reduction in RBC was observed on day 4th. When Ashwagandha (300mg/kg b.w.) administered five days prior to cyclophosphamide administration and continued for ten days then significant increase in total count of WBC, ALC and Platelets were observed after treatment but there is no significant statistical difference in the RBC count was seen in all groups during the period of the study. Thus findings of present investigation showed that therapeutic potency of Ashwagandha ameliorate the toxicity produced during cancer chemotherapy by mitigating the bone marrow depression.

Aegle marmelos, a plant having tremendous therapeutic potential, the importance seems largely due to its medicinal properties and all the parts viz. roots, leaves, fruits, bark and seeds are used for curing human ailment. In the present investigation, the anticlastogenic potential of hydromethanolic Aegle marmelos (AM) leaves extract has been evaluated using in vivo Micronucleus assay in Swiss albino mice. Cyclophosphamide (CP), a well known mutagen was given intraperitoneal (i.p.) injection at the dose of 50 mg/kg bodyweight (b.w.). AM leaves extract at the doses of 450, 675, 900 mg/kg b.w. provided protection when given 24 hrs. prior to CP administration. In CP treated animals, a significant induction of micronucleus was recorded and in different AM extracts supplemented groups, a dose dependent significant decrease in CP induced clastogenicity was observed which was statistically significant (p